α cd4 clone gk1

Manufactured by BioXCell

α-CD4 (clone GK1.5) is a monoclonal antibody that binds to the CD4 receptor on T cells. It is commonly used in flow cytometry and other immunological applications to identify and isolate CD4+ T cells.

Automatically generated - may contain errors

Lab products found in correlation

α cd8 clone 2, by BioXCell (3 mentions) α pd 1 clone rmp1 14, by BioXCell (2 mentions) αnk1.1 clone pk136, by BioXCell (1 mentions) Clone ltf 2, by BioXCell (1 mentions) Clone mopc 21, by BioXCell (1 mentions) αcd8 clone 53 6, by Thermo Fisher Scientific (1 mentions) Isotype control clone ltf 2, by BioXCell (1 mentions)

4 protocols using α cd4 clone gk1

Modulating Antitumor Immunity via Checkpoint Inhibitors

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

200μg of α-CD8 (clone 2.43, BioXCell), α-CD4 (clone GK1.5, BioXCell), α-PD-1 (clone RMP1–14, BioXCell), or respective isotype controls were administered to mice via intraperitoneal injection on days 5, 7, 9, and 11 post-initial tumor challenge. NK cell depletion experiments followed the same dosing protocol, using 250μg of α-NK1.1 (clone PK136, BioXCell). CLEC9A blocking experiments followed the same dosing protocol, using 400μg of α-CLEC9A (clone 7H11, BioXCell) or isotype control, as described (28 (link)).

Snyder A.G., Hubbard N.W., Messmer M.N., Kofman S.B., Hagan C.E., Orozco S.L., Chiang K., Daniels B.P., Baker D, & Oberst A. (2019). Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates anti-tumor immunity. Science immunology, 4(36), eaaw2004.

+ Open protocol

+ Expand

Modulating Immune Responses with Targeted Antibodies

Check if the same lab product or an alternative is used in the 5 most similar protocols

For immunotherapy regimen, 250 μg of agonist antibodies (αCTLA4 clone UC10–4F10–11; αPD1 clone RMP1–14; BioXCell) were given by intraperitoneal (i.p.) injection; αPD1 was given every 4 days for a total of 30 days and αCTLA4 was given every 5 days for a total of 4 doses from beginning of treatment. Treatments were discontinued after 30 days to prevent α-rat IgG reaction.
For T cell depletion, CD4 or CD8 neutralizing IgG antibodies (αCD4 clone GK1.5; αCD8 clone 2.43, BioXCell) were administered, with 1^st injection (at day −2) containing 400 μg and subsequent injections (every 4 days) containing 200 μg of each IgG. Treatments were discontinued after 30 days. As control, rat IgG2b isotype control (clone LTF-2, BioXCell) was administered.
For type-I IFN neutralization, αIFNAR1 (clone MAR1–5A3, BioXCell) antibody was administered, with 1^st injection (at day −2) containing 750 μg and subsequent injections (every 3 days) containing 250 μg of each IgG. Treatments were discontinued after 30 days. As control, mouse IgG1 isotype control (clone MOPC-21, BioXCell) was administered.

Lander V.E., Belle J.I., Kingstonl N.L., Herndon J.M., Hogg G.D., Liu X., Kang L.I., Knolhoff B.L., Bogner S.J., Baer J.M., Zuo C., Borcherding N.C., Lander D.P., Mpoy C., Scott J., Zahner M., Rogers B.E., Schwarz J.K., Kim H, & DeNardo D.G. (2022). Stromal reprogramming by FAK inhibition overcomes radiation resistance to allow for immune priming and response to checkpoint blockade. Cancer discovery, 12(12), 2774-2799.

+ Open protocol

+ Expand

T Cell Depletion in Mouse Model

Check if the same lab product or an alternative is used in the 5 most similar protocols

α-CD4-clone GK1.5 (catalog no. BE0003-1), α-CD8-clone 2.43 (catalog no. BE0061), and isotype control-clone LTF2 (catalog no. BE0090) depletion antibodies were purchased from Bio X Cell Inc. C57BL6/J WT mice were treated every other day, starting at −2 dpi, with 400 μg each of α-CD4 and α-CD8 antibodies, or 800 μg of isotype control, until 6 dpi. On day 7 after infection, mice were humanely euthanized, and T cells were analyzed by flow cytometry using α-CD4-clone RM4-5 (BD Pharmingen) and α-CD8-clone 53-6.7 (eBioscience) antibodies.

Imbiakha B., Sahler J.M., Buchholz D.W., Ezzatpour S., Jager M., Choi A., Monreal I.A., Byun H., Adeleke R.A., Leach J., Whittaker G., Dewhurst S., Rudd B.D., Aguilar H.C, & August A. (2024). Adaptive immune cells are necessary for SARS-CoV-2–induced pathology. Science Advances, 10(1), eadg5461.

+ Open protocol

+ Expand

CD4 Depletion and Cytokine Neutralization in C. difficile Infection

Check if the same lab product or an alternative is used in the 5 most similar protocols

For CD4 cell depletion: DSS-treated and untreated mice were injected i.p. with 400μg α-CD4 (clone GK1.5, BioXcell Cat# BE0003–1, RRID:AB_1107636) or IgG isotype control (BE0090, BioXcell Cat# BE0090, RRID:AB_1107780) on days −6, −3 and on the day of infection with C. difficile as previously reported (Moynihan et al., 2016 ). Flow cytometry was used to confirm depletion of CD4-expressing T cells from the colon with 90% efficiency.
For IL-17RA blockade and IL-17A neutralization: DSS-treated mice were injected i.p. with 125μg α-IL-17RA (R&D Systems, Cat# MAB4481, RRID:AB_10891109), 125μg αIL-17A (R&D Systems, Cat# MAB421, RRID:AB_2125018) or IgG isotype control (R&D Systems, Cat# MAB006, RRID:AB_357349) on days −1, 1 and 2 of C. difficile infection.

Saleh M.M., Frisbee A.L., Leslie J.L., Buonomo E.L., Cowardin C.A., Ma J.Z., Simpson M.E., Scully K.W., Abhyankar M.M, & Petri WA J.r. (2019). Colitis-induced Th17 cells increase the risk for severe subsequent Clostridium difficile infection. Cell host & microbe, 25(5), 756-765.e5.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!